The Story of Anybody, Somebody, Nobody and Everybody  by Naylor, A.R. & Ricco, J.-B.
LEADING ARTICLEFrom the Editors
The Story of Anybody, Somebody, Nobody and Everybody
A.R. Naylor, MD a,*, J.-B. Ricco, MD, PhD b“There was an important job to be done. Everybody thought
Somebody would do it. Anybody could have done it; but
Nobody did it. Somebody got angry because he thought it
was Everybody’s job to do it. In the end; Everybody blamed
Somebody, when Nobody did what Anybody could have
done!”
ANON
In this issue of the EJVES; ACST-2 publishes safety data in
asymptomatic patients following carotid endarterectomy
(CEA) and carotid artery stenting (CAS), observing that the
30-day combined rate of death, disabling stroke or fatal
myocardial infarction was 1%.1 There are no parallel
data from CREST,2 but the 30-day rate of death/any stroke
following CAS and CEA in ACST-2 is currently about
3.3%, compared to 1.9% in CREST.2 Accordingly, while the
overall procedural risks are not dissimilar to those following
CEA in ACST-1,3 the ACST-2 Trial Collaborators can be
conﬁdent that their interventions are conferring a low risk
of death/disabling stroke.
So how does this data inform the current debate? The
management of asymptomatic carotid disease remains
enduringly controversial. Despite 2011 American Heart
Association (AHA) Guidelines advising that CAS could now
be considered as an alternative to CEA in ‘average risk’
asymptomatic patients,4 there is still much disagreement as
to how best to treat these patients. This was evident when
the Centres for Medicare & Medicaid Services (CMS)
convened a January 2012 meeting of the Medicare Evidence
Development & Coverage Advisory Committee (MEDCAC)
to determine whether CAS coverage should be expanded to
include ‘average risk’ patients with asymptomatic carotid
disease.5
The MEDCAC panel considered the same evidence base
as the AHA, but when asked whether they were conﬁdent
that there was adequate evidence to determine whether
CAS, CEA or best medical therapy (BMT) was the favoured
strategy in the ‘average risk’ Medicare population witha
Department of Vascular Surgery, Leicester Royal Inﬁrmary, Leicester, UK
b
Vascular Surgery Department, Jean-Bernard Hospital, University of Poitiers,
Poitiers, France
* Corresponding author. A.R. Naylor, MD, Vascular Research Group,
Division of Cardiovascular Sciences, Clinical Sciences Building, Leicester
Royal Inﬁrmary, Leicester LE27LX, UK. Tel.: þ44 116 2523252; fax: þ44 116
2523179.
E-mail address: ross.naylor@uhl-tr.nhs.uk (A.R. Naylor).
1078-5884/$ e see front matter  2012 European Society for Vascular
Surgery. Published by Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ejvs.2012.11.003asymptomatic carotid disease, the pooled consensus was
that there was low conﬁdence that CEA or CAS was
appropriate. There was, however, a signiﬁcantly higher level
of conﬁdence that BMT was preferable.5 This interpretation
of the literature is very similar to what was reported
previously in an online audit in the NEJM where 50% of
5000þ respondents said they would not subject an
asymptomatic patient to CEA or CAS.6
The main reason for the lack of conﬁdence regarding the
evidence for supporting either CEA or CAS at MEDCAC was
a growing awareness that the modern concept of BMT has
probably reduced the average annual rate of stroke in
patients with asymptomatic carotid disease,7 to the extent
that ACAS and ACST data may no longer be relevant in the
modern era.3,8 Data suggest that there has been a sustained
decline in the annual rate of ‘any’ and ipsilateral stroke,
irrespective of stenosis severity at baseline.9 In addition,
and notwithstanding the excellent ACST-2 safety data,
evidence suggests that even if it were possible to perform
CEA or CAS with a zero percent risk, about 93% of all
interventions in asymptomatic individuals would still prove
ultimately unnecessary.9
At this moment in time, three randomised trials are
recruiting patients with asymptomatic carotid disease (ACT-
1, ACST-2 and SPACE-2). A fourth (CREST-2) is currently in
preparation and an application for funding is expected
shortly. Each have different methodologies, though it has
been suggested that this degree of heterogeneity should be
viewed as a positive feature as it enables clinicians to
identify a trial that best suits their equipoise. For example; if
you believe that your asymptomatic patient does require an
intervention (but are not sure whether it should be CEA or
CAS), he/she can be randomised within ACT-1 or ACST-2. If,
however, you are uncertain as to whether any intervention
is appropriate, these patients can be randomised within
SPACE-2. This is because, unlike ACT-1 and ACST-2, SPACE-2
includes a limb for BMT. SPACE-2 initially planned to
compare intervention (CEA or CAS) vs BMT alone, but
a recent protocol change means that patients will now be
randomised to either CEA vs BMT or CAS vs BMT (according
to clinician preference). By contrast, CREST-2 plans to have
a three-arm trial that will include randomisation to CEA,
CAS or BMT alone.
So will the combination of these four studies enable
Guideline makers and any future MEDCAC panel decide
how best to treat patients with asymptomatic carotid
disease? Unfortunately, the answer is probably no as there
is still an ‘elephant in the room’. Notwithstanding the claim
by ACST-2 that their trial is suitable for clinicians who are
A.R. Naylor and J.-B. Ricco 507conﬁdent that their patient requires an intervention (but
not which), the inescapable fact is that no one has devel-
oped any validated criteria for identifying this type of
patient (i.e. high risk for stroke and hence will beneﬁt from
intervention). Secondly, it would seem that neither SPACE-2
nor CREST-2 intend to include any form of risk-stratiﬁcation
(beyond stenosis severity) that might enable ‘high risk for
stroke’ patients to be identiﬁed in those that are rando-
mised to BMT. Unfortunately, simply recruiting asymptom-
atic patients based upon stenosis severity is a failed
experiment as was evident in both ACAS and ACST.3,8
Accordingly, there is a very real risk that a lot of money and
a great deal of effort could be expended in the performance
of large-scale randomised trials with the very real possibility
that exactly the same questions (posed to MEDCAC)
regarding roles for CEA, CAS and BMT in ‘average risk’
asymptomatic patients will remain unanswered. It is now too
late for ACT-1 and ACST-2 to change their protocol and
include a risk-stratiﬁed medical limb (their methodology and
funding was secured well before the current debate inten-
siﬁed) and there does not (currently) seem to be any realistic
prospect of SPACE-2 being able to secure the additional
funding required to evaluate risk stratiﬁcation based on
imaging protocols in medically treated patients. That leaves
CREST-2. Their ﬁnal protocol has not been made public, but it
may be the only realistic chance of performing an appro-
priately powered study to identify imaging features that
might be capable of identifying the relatively small cohort of
‘high risk for stroke’ patients in whom to target CEA or CAS.
There are a number of potential (and not unduly complex)
imaging strategies for consideration in CREST-2 including;
silent infarction on baseline CT/MRI, stenosis progression,
baseline cerebral vascular reserve, computerised ultrasound
plaque analysis, MR diagnosed intra-plaque haemorrhage
and, most importantly, spontaneous embolisation on trans-
cranial Doppler ultrasound.
Yes; the inclusion of imaging will incur increased trial
costs, but these pale into insigniﬁcance compared to the
cost of doing nothing. If we assume that the ACAS data do
retain some relevance in 2013, performing 1000 CEA (or
CAS) procedures with a 2% procedural risk will only prevent
50e60 strokes at ﬁve years,9 meaning that about 950
interventions (95%) were ultimately unnecessary. For US
Health Providers, this equates to about $2 billion being
spent on unnecessary interventions each year.10Surely they
might consider that investing a tiny fraction of this amounttowards helping identify a small but high-risk cohort who
would then beneﬁt from CEA or CAS is good business?
Alas; Everybody knows that a really important question
needs to be answered. Unfortunately, Nobody seems willing
to deal with it, but Somebody has to take responsibility. Is
Anybody listening or will Everybody continue to blame
Somebody, when Nobody did what Anybody could have
done?CONFLICT OF INTEREST
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